.turn on desktop notifications for breaking stories about interest?
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
he added: �these findings show that despite the tireless work of doctors and nurses, it appears that some cancer patients are still enduring shockingly long waits to start treatment.
.
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years.
.